Lexaria Bioscience (LEXX) Cash from Investing Activities Growth (3y) (2013 - 2026)
Lexaria Bioscience (LEXX) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -44.69% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -39.73% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -246.81% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -177.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.84% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.57% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 6.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 6.97% |
| Feb 28, 2026 | -18.15% |
| Nov 30, 2025 | 47.30% |
| Aug 31, 2025 | -46.66% |
| May 31, 2025 | 19.99% |
| Feb 28, 2025 | 6.77% |
| Nov 30, 2024 | 13.40% |
| Aug 31, 2024 | -3,164.62% |
| May 31, 2024 | 32.24% |
| Feb 29, 2024 | -30.27% |
| Nov 30, 2023 | -90.66% |
| Aug 31, 2023 | -71.20% |
| May 31, 2023 | -64.97% |
| Feb 28, 2023 | -3,097.26% |
| Nov 30, 2022 | -82.74% |
| Aug 31, 2022 | -14.79% |
| May 31, 2022 | 68.71% |
| Feb 28, 2022 | -27.06% |
| Nov 30, 2021 | 29.65% |
| Aug 31, 2021 | 95.79% |